Medical Advocates
Tenofovir Disoproxil Fumarate (Viread)
   
Pediatric Data

New and Noteworthy 
Journal Citations
 Conference Citations


 
Tenofovir Main Page Main New/Newsworthy  Home Page      
Last Update:  November 12, 2016
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
November 2016
 

 
Journal Papers, Abstracts, and Commentaries
       
General Reports
 
  Tenofovir exposure in utero and linear growth in HIV exposed, uninfected infants: a prospective study.
M le Roux S, Jao J, Brittain K, . et al
 AIDS. 2016 Oct 14.
Abstract

Detectable tenofovir levels in breastfeeding infants of mothers exposed to topical tenofovir.
Noguchi LM, Montgomery ET, Biggio JR, et al
Antimicrob Agents Chemother. 2016 Jul 11.
Abstract

Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
 Palombi L, Pirillo MF, Marchei E, et al 
J Antimicrob Chemother. 2015 Dec 17.
 Abstract

Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK, Wu JW, Jacobson DL,  et al 
Pediatr Infect Dis J. 2015 May 6.
 Abstract

Safety
 
  Tenofovir Disoproxil Fumarate Safety for Women and their Infants during Pregnancy and Breastfeeding: Systematic Review.
Mofenson LM, Baggaley RC, Mameletzis I. 
AIDS. 2016 Nov 7. [
 Abstract

Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults: A 60-Month Follow-Up Study.
 Viganò A, Bedogni G, Manfredini V, et al
Clin Drug Investig. 2011;31(6):407-15.
 Abstract


Pharmacokinetics

 
  Population Pharmacokinetics of Tenofovir in HIV-1 Infected Pediatric Patients.
Bouazza N, Urien S, Hirt D, et al
J Acquir Immune Defic Syndr. 2011 Aug 18.
 Abstract

Steady-State Pharmacokinetics of Tenofovir Based Regimens in HIV-Infected Pediatric Patients.
King JR, Yogev R, Jean-Philippe P, Graham B,  et al
Antimicrob Agents Chemother. 2011 Jun 13
 Abstract

Efficacy
 
 

Tenofovir in Indian children.
Kathwate J, Shah I.
Indian Pediatr. 2015 Apr 8
 Abstract

Efficacy, Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Virologic-Suppressed HIV-infected Children Using Weight-Band Dosing.
Aurpibul L, Cressey TR, Sricharoenchai S,  et al
Pediatr Infect Dis J. 2015 Apr;34(4):392-397.
 Abstract

A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1-infected Children With Virologic Suppression.
Saez-Llorens X, Castaño E, Rathore M, et al
Pediatr Infect Dis J. 2015 Apr;34(4):376-382.
Abstract

Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
[No authors listed]
Prescrire Int. 2014 May;23(149):124-5.
 Abstract

A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected Children and Adolescents: A Report from 5 Years of Clinical Experience.
 Rosso R, Parodi A, Torrisi C, et al
AIDS Res Hum Retroviruses. 2010 Sep 28
 Abstract

Tenofovir Use in Human Immunodeficiency Virus-1-Infected Children in the United Kingdom and Ireland.
 Riordan A, Judd A, Boyd K, et al 
Pediatr Infect Dis J. 2009 Jan 29
 Abstract
 
Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children.
Gafni RI, Hazra R, Reynolds JC, Maldarelli F, et al 
Pediatrics. 2006 Aug 21;
 Abstract
 
Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection.
Hazra R, Gafni RI, Maldarelli F, et al
Pediatrics. 2005 Nov 15
 Abstract

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Hazra R, Balis FM, Tullio AN, et al.
 Antimicrob Agents Chemother. 2004 Jan;48(1):124-9.
Abstract
 
Adverse Events
 
 
In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants.
Denneman L, Cohen S, Godfried MH,  et al
AIDS. 2016 Aug 24;30(13):2135-7
 Abstract

Tenofovir-induced Renal Tubular Dysfunction in Vertically HIV-infected Patients Associated With Polymorphisms in ABCC2, ABCC4 and ABCC10 Genes.
 Giacomet V, Cattaneo D, Viganò A,  et al
Pediatr Infect Dis J. 2013 Oct;32(10):e403-5.
Abstract

Tenofovir Treatment Duration Predicts Proteinuria in a Multi-Ethnic United States Cohort of Children and Adolescents with Perinatal HIV-1 Infection.
Purswani M, Patel K, Kopp JB,  et al
Pediatr Infect Dis J. 2012 Dec 17
Abstract

FULL-TEXT PDF ARTICLE
 Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
 Pontrelli G, Cotugno N, Amodio D,  et al
BMC Infect Dis. 2012 Jan 23;12(1):18. [
 Paper

Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
Soler-Palacín P, Melendo S, Noguera-Julian A, et al 
AIDS. 2010 Nov 11
 Abstract

A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected Children and Adolescents: A Report from 5 Years of Clinical Experience.
 Rosso R, Parodi A, Torrisi C, et al
AIDS Res Hum Retroviruses. 2010 Sep 28
 Abstract

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Judd A, Boyd KL, Stöhr W, AIDS. 2010 Feb 4.
 Abstract

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
Purdy JB, Gafni RI, Reynolds JC
J Pediatr. 2008 Apr;152(4):582-4.
 Abstract
 
Increased beta-2 Microglobulinuria in HIV-1-Infected Children and Adolescents Treated with Tenofovir
Papaleo A, Warszawski J, Salomon R, et al 
Pediatr Infect Dis J. 2007 Oct;26(10):949-951.
 Abstract
 
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Hussain S, Khayat A, Tolaymat A, Rathore MH.  
Pediatr Nephrol. 2006 May 16;
 Abstract

A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children.
Giacomet V, Mora S, Martelli L, et al
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):448-450.
 Abstract
 
Treatment Strategies
 
  Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
 Fabiano V, Giacomet V, Viganò A, et al
Eur J Pediatr. 2013 May 1.
 Abstract
Conference Reports, Abstracts, and Posters
       
 

POSTER
 Tenofovir associated proximal renal tubular dysfunction in HIV-positive children and adolescents
A. Camacho-Gonzalez, L. Greenbaum, R. Chakraborty, et al
(XIX International AIDS Conference)
Poster     Abstract
FDA Updates
       
  NEWS RELEASE
FDA Approves New Pediatric Dosing Recommendations for a New 75 mg Prezista Tablet
US FDA
December 18. 2008
News

Tenofovir Main Page Main New/Newsworthy  Home Page      

Tenofovir Pediatric Daya